Key result
KCNQ2-related encephalopathy presents with epilepsy in ~94% of patients across three neurodevelopmental severity clusters.
Why the study?
Comorbidities associated with KCNQ2-related encephalopathy and their impact on patients and families have been seldom described and remain to be investigated.
Cross-Sectional (n=80)
Yes
This family-driven survey provides extensive data on KCNQ2-DEE, identifying three severity clusters and highlighting the significant impact of comorbidities on patients and families.
Survey data link greater KCNQ2-DEE severity to more comorbidities and family burden; leaves open need for validated non-seizure outcomes in trials.
Variants of KCNQ2 are associated with a wide spectrum of disorders, ranging from Self-limiting Neonatal Epilepsy (SelNE) to Early Onset Developmental and Epileptic Encephalopathy (KCNQ2-DEE). Comorbidities associated with this end of the spectrum have been seldomly described and their impact on the life of patients and their families is yet to be investigated. Collaborating with caregivers from different European family associations, we have developed a questionnaire aimed at investigating the onset and frequency of epileptic seizures, anti-seizure medications (ASM), hospitalizations, stages of development, and comorbidities. Responses from 80 patients, 40 males, from 14 countries have been collected. Median age 7.6 years (4 months - 43.6 years). Of 76 epileptic patients (93.6%), 55.3% were seizure-free with a mean age at last seizure of 26.7 months. Among patients with active epilepsy, those older have a lower frequency of seizures (p > 0.05). We were able to identify three different clusters of varying severity (Mild, Severe, Profound), based on neurodevelopmental features and symptoms, excluding epilepsy. Patients in a higher severity cluster had a higher mean number of comorbidities, which had a higher impact on families. Notably, patients in different clusters presented different epilepsy onset and courses. This study constitutes the most extensive data collection of patients with KCNQ2-DEE, with a focus on comorbidities in a wide age group. The participation of caregivers helps to define the impact of the disease on the lives of patients and families and can help identify new primary and secondary outcomes beyond seizures in future studies.
No takes yet. Share an insight, caveat, or question.
Cossu et al. (2023) conducted a cross-sectional in KCNQ2-related encephalopathy (n=80). KCNQ2 variants was evaluated on Epilepsy characteristics and comorbidities. Among 80 patients with KCNQ2-related encephalopathy, 93.6% had epilepsy (55.3% seizure-free), and patients were grouped into three severity clusters based on neurodevelopmental features and comorbidities.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: